Medacta Forecast, price target & analysts
Medacta Target price 2026 - Analyst rating & recommendation
Medacta Classifications & Recommendation
Medacta Price Target
| Target Price | CHF153.00 |
| Price | CHF114.00 |
| Potential |
34.21%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Medacta 2027 .
The average Medacta target price is CHF153.00.
This is
34.21%
register free of charge
CHF189.00
65.79%
register free of charge
CHF122.21
7.20%
register free of charge
|
|
| A rating was issued by 10 analysts: 8 Analysts recommend Medacta to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medacta stock has an average upside potential 2027 of
34.21%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million CHF | 637.58 | 717.76 |
| 15.79% | 12.58% | |
| EBITDA Margin | 19.96% | 27.85% |
| 2.90% | 39.53% | |
| Net Margin | 13.96% | 12.91% |
| 13.10% | 7.52% |
7 Analysts have issued a sales forecast Medacta 2026 . The average Medacta sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Medacta EBITDA forecast 2026. The average Medacta EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Medacta Analysts have issued a net profit forecast 2026. The average Medacta net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 4.46 | 4.64 |
| 30.79% | 4.04% | |
| P/E | 24.55 | |
| EV/Sales | 3.55 |
8 Analysts have issued a Medacta forecast for earnings per share. The average Medacta EPS is
This results in the following potential growth metrics and future valuations:
Current Medacta Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Sep 21 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| RESEARCH PARTNERS AG |
Locked
➜
Locked
|
Locked | Sep 16 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Jul 14 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jul 01 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Sep 21 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Sep 17 2026 |
|
Locked
RESEARCH PARTNERS AG:
Locked
➜
Locked
|
Sep 16 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jul 14 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jul 01 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jun 30 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
